Acute myeloid leukemia in Mexico: the specific challenges of a developing country. Results from a multicenter national registry

ConclusionsThis is the first multicenter report analyzing AML-survival in Mexico. Challenges in this setting include a high induction-related mortality and low AlloHSCT rate, which should be addressed in order to improve outcomes.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionsIn the largest real-world study, we demonstrate an association between factors such as age, comorbidity and AML subtypes, and the use of multiagent chemotherapy. The use of multiagent chemotherapy was associated with improved OS, particularly among patients younger than 70 years, good-risk AML and those with low Charlson comorbidity score.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionOur study did not find a statistically significant difference in the overall response rates or survival outcome measures for patients with AML and indeterminate day 14 bone marrow in the 2 treatment groups. Our findings question the utility of immediate reinduction chemotherapy and raise concern regarding overtreatment in this patient population. Larger studies investigating similar outcomes are warranted to validate our clinical findings.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsThe high ORR and reasonable duration of response could allow for potentially curative allogeneic hematopoietic cell transplantation for these patients with high-risk AML. Our initial data suggest that lenalidomide plus HMA is a promising approach for patients with AML with inv(3).
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 24 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yedla Rajani Priya, Stalin Chowdary Bala, Venkateswara Rao Pydi, Kuruva Siva Prasad, Rachana Chennamaneni, Meher Lakshmi Konatam, Tara Roshni Paul, Sadashivudu GundetiAbstractBackgroundAcute promyelocytic leukemia, a distinct variant of acute myeloid leukemia (AML) accounts for 10% of AML cases. Over the past decade, APL had emerged from a highly fatal disease to a highly curable one. The published data on outcomes of APL from India is scant. The present study was designed to analyse the clinicopathological features ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 24 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prajwal Dhakal, Bimatshu Pyakuryal, Prasun Pudasainee, Venkat Rajasurya, Krishna Gundabolu, Vijaya Raj BhattAbstractProspective evidence for management of therapy-related acute myeloid leukemia (t-AML) is limited, with evidence extrapolated from major AML trials. Optimal treatment is challenging and needs consideration of patient-specific, disease-specific, and therapy-specific factors. Clinical trials are recommended, especially for unfit patients or those with unfavorable cytogenetics or mutations. CPX-351 as an up...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Andre C. SchuhAbstractThe ultimate goal of treatment for acute myeloid leukemia (AML) is to improve survival, and the best means of doing so is through the induction of morphologic remission, which is historically most reliably achieved with intensive chemotherapy regimens. Older patients with AML are less likely to be candidates for or to benefit from intensive chemotherapy. Patients deemed ineligible for intensive therapy may nevertheless benefit from lower-in...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Andre C. SchuhAbstractThe ultimate goal of treatment for acute myeloid leukemia (AML) is to improve survival, and the best means of doing so is through the induction of morphologic remission, historically most reliably achieved with intensive chemotherapy regimens. Older patients with AML are less likely to be candidates for, or to benefit from, intensive chemotherapy. Patients deemed ineligible for intensive therapy may nevertheless benefit from lower intensity...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The ultimate goal of treatment for acute myeloid leukemia (AML) is to improve survival, and the best means of doing so is through the induction of morphologic remission, which is historically most reliably achieved with intensive chemotherapy regimens. Older patients with AML are less likely to be candidates for or to benefit from intensive chemotherapy. Patients deemed ineligible for intensive therapy may nevertheless benefit from lower-intensity therapies and from newly available targeted AML treatments.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Source Type: research
The ultimate goal of treatment for acute myeloid leukemia (AML) is to improve survival, and the best means of doing so is through the induction of morphologic remission, historically most reliably achieved with intensive chemotherapy regimens. Older patients with AML are less likely to be candidates for, or to benefit from, intensive chemotherapy. Patients deemed ineligible for intensive therapy may nevertheless benefit from lower intensity therapies and from newly available, targeted AML treatments.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Publication date: Available online 9 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prajwal Dhakal, Elizabeth Lyden, Andrea Lee, Joel Michalski, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj BhattAbstractBackgroundThe role of obesity in prognosis of acute myeloid leukemia(AML) is debatable. Our retrospective study aimed to determine the effect of obesity on overall survival(OS) in AML.MethodsAML patients diagnosed at University of Nebraska Medical Center were divided into 3-groups based on body mass index (BMI): normal(18.5-25kg/m2) or underweight(
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Leukemia | Lymphoma | Mexico Health | Myeloma | Study